Latest filing published 09 Oct 2025 for aTYR PHARMA INC, €527k. Read the official filing
Across 3 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Paul Schimmel is a declared insider of aTYR PHARMA Inc (board member), with filings sourced from SEC (Form 4). Between 16 September 2015 and 8 October 2025, the trades on record add up to 7 filings.
No open-market sale appears; the market trades are 5 purchases worth €2.9M. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. Outside the open market, there are 1 option exercise. In 2025 alone, the filings show 1 purchase and no sales.
Half of the purchases are above €410k and half below. 1 out of 5 purchases came within 30 days of a purchase by at least one other insider of the same company. Purchases made close together by different insiders form what is called a cluster.
The record was last updated on 9 October 2025 with an open-market purchase (€527k) in aTYR PHARMA Inc. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 2 days. US insiders must file a Form 4 within two business days of a trade. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
7 of 7 declarations